MedPageToday -- GOTHENBURG, Sweden -- Women were almost twice as likely as men to discontinue initial disease-modifying therapy for a multiple sclerosis-related clinically isolated syndrome (CIS), researchers reported here.
MedPageToday -- GOTHENBURG, Sweden -- Women were almost twice as likely as men to discontinue initial disease-modifying therapy for a multiple sclerosis-related clinically isolated syndrome (CIS), researchers reported here.
